WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon Give Kids a Chance Act is a victory for children and families living with rare diseases. We applaud the House for their commitment to this life-saving measure, and to a key part of the bill – the reauthorization of the Pediatric Priority Review Voucher program.This commonsense legislation brings hope to the families of the sickest children by renewing a program, which, for more than a decade, has helped incentivize the development of treatments for rare pediatric diseases at no cost to taxpayers. We urge the Senate to get this essential legislation across the finish line and reauthorize the PPRV program.”###About the Biotechnology Innovation Organization (BIO)BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.